Article
Tampa, Fla. — Among molecularly targeted agents being developed to treat melanoma, some of the most exciting are anti-CTLA-4 antibodies now being developed by Pfizer and Medarex.
Conference Recap: 2024 Society of Dermatology Physician Associates Fall Dermatology Conference
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881
Review Compares Psoriasis Therapies in Asian Populations